Clinical trial
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects With Pulmonary Arterial Hypertension
NCT02234141 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects With Pulmonary Arterial Hypertension
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2014
- Completion date
- December 31, 2016
- Enrollment
- 151 (actual)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.